文献速递血栓与止血造血干细胞移植与细胞治疗

通过祖先序列重建鉴定活性增强的凝血因子IX变体

Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction.
PubMed 文献 · Blood Adv · 2021-01-01

本研究利用祖先序列重建(ASR)平台复活了一系列古代哺乳动物凝血因子IX(FIX)变体,旨在筛选更优的药物候选。其中一个变体An96的FIX活性产量比人FIX高12倍,加入R338L Padua突变后活性进一步增加,提示机制独立但叠加。在血友病B小鼠中,AAV2/8-An96-Padua基因治疗后的血浆FIX活性比AAV2/8-人FIX-Padua高10倍,并通过隐静脉出血挑战和血栓弹力图证实了表型纠正。

要点

  • An96变体的FIX活性产量比人FIX高12倍。
  • R338L Padua替换可进一步增加An96活性,机制独立但叠加。
  • AAV2/8-An96-Padua在小鼠中血浆FIX活性比人FIX-Padua高10倍。

核心结论

  • ASR平台可有效鉴定活性增强的FIX变体,An96-Padua是有前景的药物候选。

研究设计与样本

  • 利用祖先序列重建复活古代哺乳动物FIX变体,并在血友病B小鼠中评估AAV2/8介导的基因治疗。

主要发现

  • An96变体的FIX活性产量比人FIX高12倍。
  • 加入R338L Padua替换后An96活性进一步增加,提示独立但叠加机制。
  • AAV2/8-An96-Padua治疗的血友病B小鼠血浆FIX活性比AAV2/8-人FIX-Padua高10倍。
  • 隐静脉出血挑战和血栓弹力图证实了祖先变体的表型纠正。

临床怎么用

  • ASR可作为发现治疗性蛋白变体的平台,An96-Padua候选需进一步临床前和临床开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Orthologous proteins contain sequence disparity guided by natural selection. In certain cases, species-specific protein functionality predicts pharmacological enhancement, such as greater specific activity or stability. However, immunological barriers generally preclude use of nonhuman proteins as therapeutics, and difficulty exists in the identification of individual sequence determinants among the overall sequence disparity. Ancestral sequence reconstruction (ASR) represents a platform for the prediction and resurrection of ancient gene and protein sequences. Recently, we demonstrated that ASR can be used as a platform to facilitate the identification of therapeutic protein variants with enhanced properties. Specifically, we identified coagulation factor VIII (FVIII) variants with improved specific activity, biosynthesis, stability, and resistance to anti-human FVIII antibody-based inhibition. In the current study, we resurrected a panel of ancient mammalian coagulation factor IX (FIX) variants with the goal of identifying improved pharmaceutical candidates. One variant (An96) demonstrated 12-fold greater FIX activity production than human FIX. Addition of the R338L Padua substitution further increased An96 activity, suggesting independent but additive mechanisms. after adeno-associated virus 2 (AAV2)/8-FIX gene therapy, 10-fold greater plasma FIX activity was observed in hemophilia B mice administered AAV2/8-An96-Padua as compared with AAV2/8-human FIX-Padua. Furthermore, phenotypic correction conferred by the ancestral variant was confirmed using a saphenous vein bleeding challenge and thromboelastography. Collectively, these findings validate the ASR drug discovery platform as well as identify an ancient FIX candidate for pharmaceutical development.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Knight KA, Coyle CW, Radford CE, et al. Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction. Blood Adv. 2021. PMID: 34477814. doi:10.1182/bloodadvances.2021004742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。